Hand-out
Press Releases
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
WALTHAM, Mass., Nov. 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine
